ROLE AND SIGNIFICANCE OF ASPROSIN IN OBESITY AND REPRODUCTIVE DYSFUNCTION IN WOMEN
Keywords:
asprosin, insulin resistance, obesity, appetite, infertility, PCOS, FBN1Abstract
Objective. Obesity has become a global epidemic, affecting more than 600 million people worldwide. WHO reports that in 2022, 2.5 billion adults (18 years and older) were overweight. Of these, 890 million were living with obesity. In 2022, 37 million children under the age of 5 were overweight. According to statistical studies, women are more prone to excessive weight gain compared to men, and therefore, by 2025, the incidence of obesity among the female population is expected to increase to 50%. It leads to reproductive dysfunction as infertility, miscarriages, premature birth, stillbirth, congenital anomalies and prematurity and high risk of C-section. Thus it is important to explore physiology of metabolic disorders and find new diagnostic methods. In this regard, attention to the physiology of adipokines has been increasing in recent years. Aim: to study the history of discovery of adipokines, especially asprosin, chemical structure, mechanism of action, receptors, assessment of aspects related to eating behavior, insulin sensitivity, obesity, diabetes. Correlation of the amount of asprosin with anthropometric indicators, biochemical analyzes and instrumental examinations. Studying it’s importance in women's reproductive system diseases. Materials and methods: scientific literature on female reproductive system pathologies and asproin in PubMed, Medscape, Elseveir, ResearchGate, GoogleScholar electronic databases. Results: Asprosin receptors are located in various tissues and organs of the body and can cross the blood-brain barrier. It was positively correlated with BMI (body mass index), cholesterol, and blood glucose. The change in the amount of asprosin in accordance with the menstrual cycle of women and its increase in proportion to the concentration of testosterone in women shows the effect on the female reproductive system. Conclusion: obesity is now becoming a global problem. This causes the increase of infertility especially among women of reproductive age. This creates the need for a deeper study of the pathophysiology of obesity, development of new methods for diagnosis and treatment. Although many studies have been conducted on asprosin and results have been obtained, many mechanisms are still unexplored and require further research.
References
Салимханов Р.Х. Шарифуллин В.Р., Кушнарева Ю.Р., Каде А.Х., Роль и значение аспросина в регуляции пищевого поведения и метаболизма. [Journal] // Кубанский научный медицинский вестник.. - 2020. - 1 : Vol. 27. - pp. 96-104.
AI. Mazur-Bialy Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature. [Journal] // Nutrients.. - 2021 Feb.
Alan M Gurlek B, Yilmaz A, Aksit M, Aslanipour B, Gulhan I, Mehmet C, Taner . Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. [Journal] // Gynecol Endocrinol.. - 2019 Mar.
Broughton DE Moley KH. Obesity and female infertility: potential mediators of obesity's impact. [Journal] // Fertil Steril.. - 2017 Apr.
Chase Romere Clemens Duerrschmid, Asprosin, a Fasting-Induced Glucogenic Protein [Journal] // Cell. - 2016, April 21.
Chase Romere Clemens Duerrschmid, Juan Bournat, Petra Constable, Mahim Jain . Author manuscript [Journal] // PMC. - 2017 April 21.
Duerrschmid C He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M, Jia P, Zhao Z, Farias M, Wu Q, Milewicz DM, Sutton VR, Moore DD, Butte NF, Krashes MJ, Xu Y, Chopra AR. Asprosin is a centrally acting orexigenic hormone. [Journal] // Nat Med.. - 2017 Dec;23. - Vol. 12. - pp. 1444-1453.
Feng B Liu H, Mishra I, Duerrschmid C, Gao P, Xu P, Wang C, He Y. Asprosin promotes feeding through SK channel-dependent activation of AgRP neurons. [Journal] // Sci Adv. 2023. - Feb 22. - 9.
Hu G Si W, Zhang Q, Lv F. Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study. [Journal] // Circulating asprosin, irisin, and abdominal obesity in Chinese patients with type 2 diabetes mellitus: a case-control study.. - 2023. - pp. 55-62.
Korek E Krauss H. Novel adipokines: their potential role in the pathogenesis of obesity and metabolic disorders. [Journal] // Postepy Hig Med Dosw. - 2015 Jan. - Vol. II.
Leonard AN Shill AL, Thackray AE, Stensel DJ, Bishop NC. Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women. [Journal] // Eur J Appl Physiol.. - 2021 Mar.
Li X Liao M, Shen R, Zhang L, Hu H, Wu J, Wang X, Qu H, Guo S, Long M, Zheng H. Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases. [Journal] // Mediators Inflamm.. - 2018 Nov.
Ozturk HA Arici FN. Achilles tendon thickness and serum asprosin level significantly increases in patients with polycystic ovary syndrome. [Journal] // PeerJ.. - 2024 Aug.
Shabir K Brown JE, Afzal I, Gharanei S, Weickert MO, Barber TM, Kyrou I, Randeva HS. Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease: Comprehensive review of preclinical and clinical evidence. [Journal] // Cytokine Growth Factor Rev.. - 2021 Aug;. - pp. 120-132.
Ugur K. Aydin S. Saliva and blood asprosin hormone concentration associated with obesity [Journal] // International journal of endocrinology.. - 2019. - 1.
